Menarini Group and Insilico Medicine enter global exclusive license agreement for novel KAT6 inhibitor for potential breast cancer treatment and other oncology indications
● KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. Credit: Insilico Medicine ● KAT6 is an emerging target in hormone sensitive